Curis (CRIS) Non Operating Income (2010 - 2026)
Curis' (CRIS) quarterly Non Operating Income came in at -$12.7 million in Q1 2026, down 2662.53% YoY from $494824.0 in Q1 2025, and down 4721.29% on a QoQ basis from -$263000.0 in Q4 2025.
Curis (CRIS) Non Operating Income (2010 - 2026) Analysis & Trends
Curis (CRIS) has 14 years of Non Operating Income data on file, last reported at -$12.7 million in Q1 2026.
- Quarterly Non Operating Income fell 2662.53% year-over-year to -$12.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$14.1 million (down 14050.5% YoY) and the FY2025 annual result came in at -$1.9 million, down 262.1% from the prior year.
- Non Operating Income declined to -$12.7 million in Q1 2026, from -$263000.0 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $709000.0 in Q2 2024 to a low of -$12.7 million in Q1 2026.
- A 5-year average of -$948764.7 and a median of -$342000.0 in 2025 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2024 — Non Operating Income soared 772.06% — and 2026, when it slumped 2662.53%.
- Tracing CRIS's Non Operating Income over 5 years: stood at -$1.1 million in 2022, then surged by 143.91% to $487000.0 in 2023, then tumbled by 228.13% to -$624000.0 in 2024, then jumped by 57.85% to -$263000.0 in 2025, then plunged by 4721.29% to -$12.7 million in 2026.
- The last three Non Operating Income figures came in at -$12.7 million (Q1 2026), -$263000.0 (Q4 2025), and -$805000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Curis | 3.27 Mn | -2.35 Mn | - | 1.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -12.68 Mn |
| Dec 31, 2025 | -263,000.00 |
| Sep 30, 2025 | -805,000.00 |
| Jun 30, 2025 | -342,000.00 |
| Mar 31, 2025 | -459,000.00 |
| Dec 31, 2024 | -624,000.00 |
| Sep 30, 2024 | 475,000.00 |
| Jun 30, 2024 | 709,000.00 |
| Mar 31, 2024 | 593,000.00 |
| Dec 31, 2023 | 487,000.00 |
| Sep 30, 2023 | 187,000.00 |
| Jun 30, 2023 | 177,000.00 |
| Mar 31, 2023 | 68,000.00 |
| Dec 31, 2022 | -1.11 Mn |
| Sep 30, 2022 | -688,000.00 |
| Jun 30, 2022 | -879,000.00 |
| Mar 31, 2022 | -976,000.00 |
| Dec 31, 2021 | -1.05 Mn |
| Sep 30, 2021 | -1.00 Mn |
| Jun 30, 2021 | -188,000.00 |